This place is about more than a pharmaceutical career. It’s about making a real difference in the lives of patients. That’s why we’re here. That’s why you should maybe think about being here, too.Our mission is to build the leading endocrine company that consistently pioneers new therapeutics to help patients better control their disease and improve their daily lives. Working to accomplish this mission is how we bring our vision to life. For us, that vision is the best possible therapeutics available to all patients with diseases of the endocrine system. We love how that sounds. And we really can’t wait to know how it feels.

National Institutes of Health

Bain Capital Life Sciences

Deep Track Capital

Driehaus Capital Management

Frazier Healthcare Partners

OrbiMed

Perceptive Advisors

RA Capital Management

Vivo Capital

5AM Ventures

Versant Ventures

Crinetics Pharmaceuticals

Viewport Meta

IPhone / Mobile Compatible

Euro

Google Tag Manager

Apple Mobile Web Clips Icon

HSTS

Google Font API

DNSSEC

WordPress

Font Awesome

Chief Human Resources Officer

Adriana Cabré

Chief Development Officer

Ajay Madan

Chief Medical Officer

Alan Krasner

Chief Business Officer

Chris Robillard

Chief Financial Officer

Marc Wilson

Founder, CEO

R. Scott Struthers

Vice President, Investor Relations and Communications

Charles Schultz

VP, Corporate Strategy and Commercial Planning

Gina Ford

Vice President, Project, Portfolio and Alliance Management

Natalie Rossignol

Vice President

Rosa Luo

Scott Struthers

Matthew Fust

Mason Freeman

Caren Deardorf

Jack Nielsen

Wendell Wierenga

Weston Nichols

Co-Founder and CEO

Yun-Fei Zhu

Co-Founder & Vice President, Chemistry

Stephen F. Betz

Vice President, Biology

Max Bronstein

Executive Director of Government Affairs and Patient Advocacy

Robert M. Cuddihy

Senior Vice President - Medical Affairs

Dana Pizzuti

Alan S. Krasner

San Diego Companies that Exited

Biotechnology Public Companies With Less Than $50M in Revenue

Western US Companies With More Than $1M in Revenue (Top 10K)

United States Public Companies With More Than 10 Employees

Crinetics Pharmaceuticals discovers and develops novel therapeutics targeting peptide hormone receptors for the treatment of endocrine-related diseases and cancers. Their programs are derived from internal discovery efforts and use objective hormonal biomarker endpoints for preclinical and clinical studies to reduce both the risk and cost to achieve meaningful clinical data. Crinetics is seeking motivated partners to help advance Their programs to become commercially successful products.

Post-IPO Equity - Crinetics Pharmaceuticals

Grant - Crinetics Pharmaceuticals

Series B - Crinetics Pharmaceuticals

National Institute of Diabetes and Digestive and Kidney Diseases

San Diego

California

United States

North America

Crinetics Pharmaceuticals to Participate in Three Upcoming December Investor Conferences

Crinetics Pharmaceuticals Announces November 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Crinetics Pharmaceuticals Officer Sells Shares

What Analysts Are Saying About Crinetics Pharmaceuticals Stock

Crinetics Pharmaceuticals, Inc. Submits New Drug Application for Paltusotine for the Treatment of Acromegaly

Crinetics Pharmaceuticals to Participate in Two Upcoming Investor Conferences

Crinetics Pharmaceuticals Expanding

Crinetics Pharmaceuticals hits all-time high at $55.78

Turkey

Europe

United Kingdom

India

Asia

Russian Federation

HTML5

Lightbox

DigiCert

jQuery

Google Fonts

Apache Server

GreenSock Animation Platform

Wordpress

Office 365

Microsoft Outlook

NexImmune is a pharmaceutical company focused on developing novel immunotherapeutics for the treatment of cancer and autoimmune diseases.

NexImmune

Mustang Bio is a clinical-stage biopharmaceutical company focused on developing novel immunotherapies for cancer and rare genetic diseases.

Mustang Bio

Adaptimmune is a biotechnology company specializing in the development of T-cell therapies for the treatment of cancer.

Adaptimmune

HBM Holdings Ltd is a diversified holding company with interests in various industries, including pharmaceuticals and healthcare.

HBM Holdings Ltd

Dynavax Technologies Corp is a biopharmaceutical company focused on developing vaccines and immunotherapies for infectious diseases and cancer.

Dynavax Technologies Corp

Crinetics Pharmaceuticals is a biotechnology company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors.

Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist that has completed phase III clinical trial for the treatment of acromegaly, as well as completed phase II clinical trial to treat carcinoid syndrome and nonfunctional neuroendocrine tumors (NETs). The company is also developing CRN04777, an oral selective nonpeptide somatostatin type 5 receptor agonist, which is in phase I clinical trial for the treatment of congenital hyperinsulinism; and CRN04894, an oral adrenocorticotrophic hormone antagonist that is in phase I clinical trial for the treatment of Cushing's and congenital adrenal hyperplasia diseases. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.

news impact assignment basic	general	Feb 12, 2024 11:26 PM	61d7bd65
public peers	general
news daily refresh	general	Dec 4, 2024 2:16 PM	8fcdc00e
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general	Feb 12, 2024 11:26 PM	6baf9c9e
company summary	general
signals	general
crunchbase trigger	general	Nov 25, 2024 9:06 AM	9b73fa26
crunchbase profile	general	Nov 25, 2024 11:35 AM	70487d5a
li profile	general	Feb 12, 2024 11:26 PM	8d4846bd
translate crunchbase fundingrounds	general	Nov 25, 2024 2:14 PM	2d700984
peers	general	Feb 12, 2024 11:26 PM	97a5d0b6
news basic	general	Dec 4, 2024 2:13 PM	7fe9acd8
bundesanzeiger	filings
financials download nd	financials
private financials	financials

COM:CRINETICS

Crinetics Pharmaceuticals

Last Close

57.03

22/11 21:00

Market Cap

4.01B

Beta: -

Volume Today

1.02M

Avg: -